A COMPARATIVE STUDY ON THE EFFECTIVENESS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIs) AND ANGIOTENSIN RECEPTOR BLOCKERS (ARBs) IN DIABETIC NEPHROPATHY IN TYPE 2 DIABETES MELLITUS PATIENTS
Keywords:
Diabetic nephropathy, Angiotensin Converting enzyme, Angiotensin Receptor blockersAbstract
Objective: To observe the clinical outcomes on usage of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in type 2 diabetic nephropathy patients.
Methods: A total 70 patients diagnosed with diabetic nephropathy were treated with ACEIs or ARBs were enrolled in this study. The data was collected from the out patients and the physician. A data collection form was used for collecting patient data. The form was used to record the details of patient's demographics, history of diabetes mellitus, duration of diabetes mellitus co morbidities, food habits and laboratory parameters such as serum creatinine, HbA1c and all the relevant things. The study has obtained ethical clearance from the institution ethics committee (IEC).
Results: The study showed middle aged patients were more prone to diabetes and pre-existing hypertension is a major risk factor for diabetic nephropathy. Majority of the patients had long duration of diabetes mellitus which indicates the strong relation between duration of diabetes mellitus with diabetic nephropathy. Compared to ACE inhibitors, ARBs decreased the level of renal parameters. This reveals the better reno-protective effect of ARBs over ACE inhibitors. ARBs had more beneficial effects in reducing the major risk factor like proteinuria in diabetic nephropathy. A considerable reduction in HbA1c values were also observed in patients using ARBs.
Conclusion: While comparing the improvement in proteinuria and the laboratory outcomes, ARBs were beneficial relatively to the ACEs in patients with diabetic nephropathy.
Â
Downloads
References
Joseph J Saseen, Barry L Carter. Hypertension. In: Joseph T Dipro. VI edition. Pharmacotherapy a pathophysiologic approach; 2008. p. 205-7.
American diabetes association. Standards of medical care in diabetes; 2013. p. 511-66.
Packham DK, Alves TP, Dwyer JP, Atkins. Relative incidence of ESRD vs cardiovascular mortality in protein uric type 2 diabetes and nephropathy. Am J Kidney Dis 2011;59:75-83.
V Mohan, S Sandeep, R Deepa, B Shah, Varghese. Epidemiology of type 2 diabetes. Indian scenario. Int J Mater Res 2007;125:217-30.
Burnier M, Brunner HR. Angiotensin II receptor antagonist. Lancet 2000;355:637-45.
Olin BR, St Lowis J, B Lippincott. Drug Facts and Comparison; 2002. p. 1,4-8,5.
George L Bakris, Matthew R Weir, Shahnazshanifer, Zhongxin Zhang, Janice Douglas, David J Van Dijik, et al. Bernner: effect of blood pressure level on progression of diabetic nephropathy. AIM 2003:163:1555-65.
Giancarlo viberti, Nigel M Wheeldon. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus a blood pressure independent effect. Circulation 2002;106:672-8.
SankyopharmaInc (us) Benicar New York: Advantage communications and the paradigram for hypertension management with new angiotensin II receptor blockers; 2002.
American Diabetes Association. Position statement: nephropathy in diabetes. Diabetes Care 2004;27(Suppl 1):s79-s83.
Fujisawa T, Ikegami H, Ono M. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin–converting enzyme inhibitor in diabetic nephropathy. Am J Hypertension 2005;18:13-7.